Evidence map›Paper›PMID 35845476›Full record

ReviewAnnals of translational medicine2022

A narrative review of cortical visual prosthesis systems: the latest progress and significance of nanotechnology for the future.

Xi Liu, Peipei Chen, Xuemeng Ding, Anning Liu, Peng Li, Cheng Sun, Huaijin Guan

Open access · diamondAbstract readReview
In one paragraph

Review in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Aerosol Jet Printing for Neuroprosthetic Device Development.Bioengineering (Basel, Switzerland) · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Seeing the Future: A Review of Ocular Therapy.Bioengineering (Basel, Switzerland) · 2024
    Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xi LiuEye Institute, Affiliated Hospital of Nantong University, Nantong, China.
Peipei ChenEye Institute, Affiliated Hospital of Nantong University, Nantong, China.
Xuemeng DingEye Institute, Affiliated Hospital of Nantong University, Nantong, China.
Anning LiuDepartment of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Nantong, China.
Peng LiDepartment of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Nantong, China.
Cheng SunKey Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Co-Innovation Center of Neuroregeneration, NMPA Key Laboratory for Research and Evaluation of Tissue Engineering Technology Products, Nantong University, Nantong, China.
Huaijin GuanEye Institute, Affiliated Hospital of Nantong University, Nantong, China.
Affiliated Hospital of Nantong University · CNNantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objective: We sought to review the latest developments in cortical visual prosthesis (CVP) systems and the significance of nanotechnology for the future. Over the past century, CVP systems have been researched and developed, resulting in various unique surgical and mechanical techniques. Research findings indicate that partial vision recovery is possible, with improvements in coarse target functions and performance in routine activities. Methods: This review discusses the architecture and physiology of the visual cortex, the neuroplasticity of the blind brain, and the history of CVP development, and also provides an update on the CVP systems currently being examined in research and clinical trials. Due to advances in nanotechnology, it is possible to make CVPs that are smaller, more efficient, and more biocompatible than ever before. Key Content and Findings: Currently, 3 CVPs have entered clinical trials, and several additional systems are undergoing preclinical reviews to determine the safety of the devices for chronic implantation. This development provides the first indication that the area of cortical vision restoration medication may be able to meaningfully benefit blind people. However, several significant technical and biological challenges need to be solved before the gap between artificial and natural eyesight can be reconciled. Rapid breakthroughs in nanotechnology have considerably increased its use in biological domains. Conclusions: This paper summarizes the recent progress of CVP in recent years and its future development direction. It is forecasted that nanotechnology can provide better technical support for the development of CVP.

Indexed as

Blindnessbrain-computer interfaceelectrode arraystimulationvisual cortex

Identifiers

PMID35845476
PMCPMC9279795
OpenAlexW4285166295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.